Table 1.

Minoxidil 1.25 mg nightly patient case series: Side‐effects, compliance, and duration of use

Patient	Age, sex	Diagnosisa	Blood pressure	Hypotensive symptoms	Fluid retention	Hair shedding	Hyper‐trichosis	Minoxidil compliance	# of Rx months
1	33, M	AGA	Not checked	No	No	No	No	Stopped ‐ stressed	6.5
2	33, F	AGA, TE	Improved	No	No	Decrease	Yes	Yes	15.25
3	37, F	AGA	n/a	n/a	n/a	n/a	n/a	Rx not filled, hypertrichosis concern	0
4	29, F	AGA, AA	Normal	No	No	No	No	Yes	10.5
5	25, F	AGA	Not checked	No	No	No	Yes	Stopped – Pill aversion	5
6	62, F	AGA	Not checked	No	No	Decrease	Yes	Yes	5.25
7	48, F	AGA	Normal	Yes, 1–2 weeks	Ankle edema	No	Yes	Yes	5.25
8	29, F	TA, AGA	Normal	No	No	No	Yes	Yes	5.5
9	54, F	AGA, FFA	Normal	No	No	Decrease	No	Yes	3
10	42, F	AGA	Not checked	No	No	Decrease	Yes	Yes	3
11	32, M	AGA, Seb D	n/r	n/r	n/r	n/r	n/r	Yes	5.5
12	20, F	AGA	Normal	No	No	No	Yes	Yes	8
13	54, F	AGA, FFA	n/a	n/a	n/a	n/a	n/a	Stopped – Topical used	0.5
14	32, F	TA	Not checked	No	No	No	No	Yes	3
15	57, F	AGA	n/a	n/a	n/a	n/a	n/a	Rx not filled, side effect concerns	0
16	25, F	TA	Not checked	No	No	No	No	Yes	14
17	65, F	AGA	Normal	No	No	No	No	Yes	7.75
18	28, F	TE, TA	Normal	No	No	No	No	Stopped – Pill aversion	1.5
19	54, F	AGA	Improved	No	No	Decrease	No	Yes	8.5
20	52, F	AGA	Not checked	No	No	Decrease	No	Yes	10.5

AGA = androgenetic alopecia; FFA = frontal fibrosing alopecia; Seb D = seborrheic dermatitis; TA = traction alopecia; TE = telogen effluvium; n/a = not applicable; n/r = no response provided; requested renewal of medication.

^aFor patients with two hair diagnoses, the more dominant presentation was deemed the primary diagnosis and is listed first.